Drug news
NICE to reassess Besponsa for CD 22 positive B cell precursor ALL.- Pfizer.
Following a successful appeal by Pfizer the National Institute for Health and Care Excellence (NICE) will reassess Besponsa (inotuzumab ozogamicin) as a treatment for adults with relapsed or refractory CD 22 positive B cell precursor Acute Lymphoblastic Leukemia. The Institute had considered that the trial evidence offered no survival benefit compared to current treatments.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins